Last Monday Ecuador announced a new cooperation agreement to be signed with China, totalling $53 million, which will allow Chinese-made medicines and vaccines to be distributed in the South American country. The agreement was signed by State-owned laboratories Enfarma, represented by Luis Monteverde, and Cui Jiao of China’s Sinopharm. The agreement will also re-start a vaccine-manufacturing plant in the country.
“Today we have set out towards a new future of integral cooperation, not only in the supply and delivery of medicine and active ingredients, but also in investment, construction and operation of pharmaceutical factories” said Jiao.
Eduardo Egas, Ecuador’s Industry and Productivity Minister, has said that “It will add… 14 additional vaccines (to the eight already made within the country), which will really help in taking care of the people’s health, especially during times like these, when many illnesses are around.” Other South American countries such as Bolivia and Cuba have signed similar agreements since 2014, hoping to break their dependence on international monopolies.
Full content: Tn8
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Subscribers Defend $4.7 Billion Antitrust Verdict Against NFL in Court Filings
Jul 19, 2024 by
CPI
Von der Leyen Calls for Competition Policy to Boost EU Companies’ Growth
Jul 19, 2024 by
CPI
Vermont AG Sues Pharmacy Benefit Managers Over Drug Prices
Jul 18, 2024 by
CPI
Australians Face Increased Stamp Prices Following ACCC Approval
Jul 18, 2024 by
CPI
Live Nation Seeks Dismissal of DOJ Antitrust Allegations
Jul 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI